Facility expansion and execution drive 56% PAT growth; capex guidance hiked
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Buy
confidence 7/10
Grade A
Hit H1 facility target (39 delivered, tracking revised 65 plan). EBITDA margins stable as guided despite greenfield drag. SSSG beat 12-16% range.
Optimistic
next 1–2 quarters
Optimistic
multi-year
Dr. Agarwal's delivered strong 56% PAT growth on 31% revenue with upward revisions to facility (60→65) and capex (₹400→500Cr) guidance. Greenfield playbook maturing; SSSG beats guidance at 18.8%. Key risk: ₹42Cr greenfield losses and execution delivery on 65 facilities amid aggressive expansion could compress margins further if ramp-up slows.
₹655.5 Cr
Revenue · +31.4% YoY₹56.9 Cr
Reported PAT · +55.8% YoYExpanding
Margins · vs guidance: CorroboratedDid the claims hold up?
Revenue from operations rose 31.4% YoY to ₹655 Cr
METDelivered result: ₹655.5 Cr, YoY +31.4%
PAT grew 55.8% YoY to ₹57 Cr for Q2
METDelivered result: ₹56.9 Cr, YoY +55.8%
PAT margin expanded to 8.5% in Q2 FY27
METDelivered NPM 8.6% (rounding difference)
18 new surgical facilities added in Q1, highest ever in single quarter
METConfirmed; total H1 additions 39 (18+21), exceeding prior 60 guidance track
SSSG at 18.8% for Q2 FY27 shows mature network has room to grow
METH1 SSSG 17.7%, Q2 18.8% — both exceed prior 12-16% guidance range
Greenfield losses of ~₹42 Cr cumulatively in H1 while margins stay stable
METEBITDA margin 28.2% H1 despite stated greenfield drag; math consistent
COGS staying in 21-22% range despite volume/mix shifts
METGross margin 78.9% implies COGS ~21%, consistent with stated range
Surgical center strategy will drive higher yields than total-center approach
METSurgical centers contribute ~80 lakhs per month; stated as ₹75-80K range
Earnings quality
What changed since the last call
Facility guidance raised
Upgrade60→65 total facilities; 40→55 surgical centers. Reflects strong H1 execution (39 delivered) and accelerated pipeline visibility.
CapEx guidance raised
Upgrade₹400Cr→₹500Cr to fund 65 vs 60 facility expansion. Shows conviction in Greenfield model despite losses.
Margin outlook maintained
NeutralEBITDA 28.2% stable despite ₹42Cr greenfield losses. No cut, no improvement guidance — holding line.
SSSG beat range
UpgradeDelivered 17.7% H1, 18.8% Q2 vs 12-16% guidance. Mature network still strong; mature facility contribution 75% of group revenue.
Acquisition strategy clarified
NewSelective bolt-on approach (₹55Cr for Dr. Anchal Gupta's 2 centers). Not aggressive; fits expansion plan, especially Delhi-NCR consolidation.
The Q&A
Analysts pressed hard on facility mix (surgical %-age, new vs mature), capex quantum, and execution cadence. Management held firm but requested follow-ups on attrition specifics and fellowship retention. Q&A tone was direct; no major evasions except on regulatory headwinds (deferred to future). Confidence in ramp-up came through.
Acquisition strategy & profile — Harith Ahamed, Avendus Spark
AnsweredYes, selective bolt-ons at right multiples in newer markets. Dr. Anchal Gupta's 2 centers in Delhi for ₹55Cr delivered ₹13.5Cr revenue, ₹7.1Cr EBITDA; 12-month payback. Strategy is organic + selective partnerships.
Capex guidance revision logic — Harith Ahamed, Avendus Spark
AnsweredRaising from ₹400Cr to ₹500Cr. Q1 had ₹400Cr guidance; now revising up to 55 surgical centers (from 40). Momentum in pipeline strong; confidence to accelerate.
Facility expansion pace sustainability — Nikhil Upadhyay, SIMPL
AnsweredPlanning happens 12-18 months in advance. In FY25, identified many sites; leases signed. Pipeline now 100 centers at various stages, filtered to 60 target. FY26 openings (96Cr revenue, 21% of mix) and FY25 (127Cr, 20%) show ramp works. Confidence from breakeven hit in many new markets.
High-end surgical mix and yield — Maulik, 360 ONE Capital
AnsweredMarket moving from LASIK to lenticular procedures (advanced refractive). Femto cataract 25.5% growth, Retinal +26.5%. High-end mix was 18% FY24, now ~30% — won't reach 50-60%. Sustained uptick as insurance penetration rises; disposable incomes up.
COGS and yield trends — Maulik, 360 ONE Capital
AnsweredCOGS staying 21-22% range. High-end procedures (cataract 30% of volume) already reflected. Won't significantly improve as mix is stabilizing. Premiumization ongoing but measured.
Facility ramp economics and losses — Maulik, 360 ONE Capital
PartialFY26 vintage 96Cr revenue, 20.9% growth (still ramping). FY25 at 127Cr, 67.8% growth. FY27 cohort will be ₹18.2Cr (6m loss) and FY26 ₹20.1Cr (6m loss). As utilization scales, losses narrow. Greenfield model proven; new centers hit breakeven faster in established markets.
Depreciation & capex impact on margins — Maulik, 360 ONE Capital
AnsweredYes, broadly that range as capex ₹500Cr deploys over FY27. Margins will absorb this; no specific uplift promised.
Doctor attrition and retention — Diya Shah, Alder C Mehta Investment
PartialOverall ~14-15%, but don't want to quantify by level. Senior level ~1-2%. Will follow up with exact numbers (6-month detail). Similar across regions.
Fellowship conversion and retention — Diya Shah, Alder C Mehta Investment
DodgedWill come back with details. Haven't shared this metric yet; needs validation.
Regulatory risk on drugs and devices — Harith Ahamed, Avendus Spark
DodgedWork with multinationals; Sun Pharma is small part of supply chain. No impact foreseen. On regulatory risk: too early to comment on government intent on IOL pricing; will update as clarity comes.
Vintaging and performance variance — Gopal Bhatt, Baroda BNP Paribas
AnsweredFY24 is early ramp. FY25 has benefit of one acquisition (Punjab Third facility — large asset). Excluding that, FY24 performs better. FY26 vintage in early ramp; FY27 will follow similar trajectory with headroom for growth.
Regional expansion pace — Delhi NCR focus — Nikhil Upadhyay, SIMPL
AnsweredYes. Already 15 centers in 15 months (since Q1 FY26). Micro-market response strong. Will add 8-12 more over 9-12m. Pipeline visibility high; lease agreements in place.
Surgical lens consumption trend — Shubh Kalra, Asit C Mehta Investment
AnsweredVolume + mix (higher-end Femto cataract, lenticular procedures). COGS staying 21-22%; no significant movement vs revenue. Lens costs staying inline with surgical growth.
Guidance
FY27 facility additions now 65 (from 60); surgical centers 55 (from 40)
HighH1 delivered 39 facilities (18+21); tracking ahead of 30 H2 plan. 55 surgical centers shows strategic shift toward higher-margin procedures. Execution track record strong.
EBITDA margin stable ~28% despite greenfield ramp
MediumH1 margin 28.2%; ₹42Cr greenfield losses offset. Depends on ramp velocity in H2 and mix stability. Finance costs rising (₹46Cr post-acquisition) could pressurize margin further.
COGS expected to stay 21-22% range
HighQ2 COGS 21.3%. Premium mix (high-end cataract ~30%) already embedded. No material improvement expected from further mix shift.
CapEx revised to ₹500Cr from ₹400Cr
HighFunding 65 vs 60 facility expansion, including 2 acquisitions (Dr. Anchal Gupta). Pipeline visibility strong; lease agreements in place; management confident in 26 H2 additions.
Risks the call surfaced
Greenfield execution & loss absorption
Medium51 new surgical facilities opened past 12m, contributing ₹42Cr cumulative losses (FY27 ₹18.2Cr, FY26 ₹20.1Cr). Ramp-up to profitability depends on utilization velocity. H2 adds 26 centers; slower-than-expected payback could pressurize EBITDA margins.
Capex intensity & debt serviceability
MediumCapEx raised to ₹500Cr from ₹400Cr (25% increase). Acquisition of Dr. Anchal Gupta's 2 centers added ₹55Cr debt (₹33Cr upfront). Finance costs jumped to ₹46Cr from ₹37Cr Q1. Sustained high capex may require more leverage; refinancing risk if rates rise.
Regulatory scrutiny on pricing
MediumGovernment policy debate on intraocular lens (IOL) markups and drug pricing (Sun Pharma halt on eye drops). Recent court interventions on device pricing. Dr. Agarwal's not directly exposed (non-drug, non-equipment manufacturer), but supply-side constraints or price controls could pressurize margins.
Talent acquisition & attrition in new markets
LowOpening 65 facilities (vs prior 60) requires accelerated hiring of specialists, surgeons, nursing staff. Overall attrition ~14-15%; senior level ~1-2%. Risk: new market entry (Delhi, Pune) may face localized talent scarcity or retention challenges.
Competitive intensity in mature markets
LowSouthern region (62% of revenue) seeing competitive entry in cataract and refractive (Apollo, Narayana, Vision India). Pricing pressure risk in Tier-1 cities (Chennai, Bangalore). West region growth (30% YoY) also seeing new entrants in Mumbai micro-markets.
Management
Score 7/10. Clear, numbers-backed. CEO Adil Agarwal articulate on strategy (Greenfield focus, facility mix shift, acquisition selectivity). CFO Yashwanth provides deep financial detail (COGS, depreciation, vintage analysis). Some hedging on attrition and fellowship retention; deferred specifics but committed to follow-up. Track record strong: Hit H1 facility additions (39 vs 30 target), SSSG beats guidance (17.7% vs 12-16% range), EBITDA margin stable (28.2%) despite greenfield ramp. Revenue growth 31.4% aligned with guidance. Only shortfall: QoQ PAT growth flat (+3.3%), suggesting near-term deceleration.
1 · H2 FY27
Launch 26 additional facilities (targeting 65 total for year); CapEx deploy ₹500Cr
2 · Nov 2026
Merger effective; delisting from BSE/NSE, consolidation into holding company
3 · FY28
Greenfield cohort (FY26-27 openings) reach maturity; margin expansion expected
Key risk: ₹42Cr greenfield losses and execution delivery on 65 facilities amid aggressive expansion could compress margins further if ramp-up slows.
Informational and educational content only. Not investment advice.